Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company generates news across medical device innovation, regulatory approvals, manufacturing expansions, and healthcare industry developments. As one of the world's largest medical technology manufacturers producing tens of billions of devices annually, BD's announcements often impact healthcare supply chains, public health initiatives, and clinical practice standards.
News coverage for BD typically encompasses product launches of safety-engineered medical devices, FDA clearances for new diagnostic instruments and drug delivery systems, and manufacturing capacity announcements that affect global medical supply availability. The company's role as a major supplier of syringes, needles, IV catheters, and diagnostic equipment means its production decisions can influence healthcare delivery capabilities, particularly during public health emergencies and vaccination campaigns.
Earnings reports reveal performance across BD's three business segments: Medical, Life Sciences, and Interventional. These disclosures provide insight into healthcare spending trends, adoption rates for new medical technologies, and geographic market dynamics across developed and emerging healthcare markets. Regulatory developments, including FDA warning letters, device recalls, or quality system issues, also generate significant news given the company's broad product portfolio and global manufacturing footprint.
Corporate developments such as acquisitions of medical device companies, divestitures of business units, strategic partnerships with pharmaceutical manufacturers, and manufacturing investments shape BD's competitive position. The company's interactions with group purchasing organizations, healthcare systems, and regulatory agencies produce news relevant to understanding healthcare economics and medical device industry dynamics.
Track BD news to monitor developments in medical device innovation, healthcare supply chain updates, regulatory compliance matters, and business performance across the company's medical technology portfolio. Understanding BD's announcements provides context on trends in hospital supply management, clinical diagnostics, and medication delivery technologies.
BD (Becton, Dickinson and Company) reported a revenue increase of 2.1% to $5.0 billion for Q2 FY2022, aided by a base revenue growth of 8.2%. However, COVID-only testing revenues fell to $214 million from $474 million. GAAP diluted EPS rose 59.6% to $1.50, while adjusted EPS was slightly down at $3.18. The company updated its fiscal 2022 guidance, projecting revenues between $19.6 and $19.8 billion, and adjusted EPS between $12.85 and $13.00. This reflects an increase in base business currency-neutral revenue growth estimates to 6.75%-7.75% and an anticipated headwind from foreign exchange.
BD (Becton, Dickinson and Company) has introduced its Scientific Advisory Board (SAB), comprising leading experts in health care, science, and technology. The board will provide insights on BD's innovation pipeline, technology capabilities, and emerging trends in the medical field. CEO Tom Polen stated that the SAB aims to enhance patient outcomes and drive growth through impactful innovations. Notable members include John DeFord from Purdue University and Claire Fraser from the University of Maryland. This strategic move is part of BD's commitment to lead in advancing health care technologies.
BD (Becton, Dickinson and Company) will present at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 12:00 p.m. Pacific Time. Investors can access the live webcast from BD's investor relations website, with a replay available post-event. BD, a leading global medical technology firm, is dedicated to advancing health through innovative technology and solutions, supporting healthcare providers and improving patient outcomes. BD boasts a workforce of 75,000 and operates globally to address significant health challenges.
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, set to be paid on June 30, 2022. Shareholders on record by June 9, 2022 will receive this payment, resulting in an annual dividend rate of $3.48 per share. This decision reflects the company's commitment to return value to its shareholders while maintaining a strong presence in global medical technology.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced the launch of BD Horizon RealYellow™ 586 Reagents, a breakthrough in flow cytometry developed using novel dye technology and AI guidance. These reagents enable improved data resolution, facilitating deeper biological insights in oncology, autoimmune disorders, and infectious diseases. The reagents support both conventional and spectral flow cytometry, allowing researchers to analyze more markers per sample. With their global availability, BD aims to enhance research capabilities and accelerate drug development.
BD (Becton, Dickinson and Company) has established the Sustainable Medical Technology Institute to enhance its environmental sustainability efforts. This initiative targets three key areas: sustainable product design, sterilization technologies, and materials of concern. By leveraging interdisciplinary expertise, BD aims to reduce the environmental impact of its products while supporting its 2030+ environmental, social, and governance (ESG) commitments. The institute will collaborate globally and set environmental criteria for new products to better meet sustainability needs.
BD (Becton, Dickinson and Company) will report its financial results for the second quarter of fiscal year 2022 on May 5, 2022, at approximately 6:30 a.m. ET. The announcement will include summary financial information for the quarter ending March 31, 2022. Management will conduct a conference call at 8 a.m. ET on the same day to discuss results and operational strategy.
Investors can access the news release and presentation materials on the company’s investor relations website.
BD (Becton, Dickinson and Company) has successfully completed its spinoff of Embecta Corp, which now operates independently, focusing on diabetes care. Shareholders received one share of Embecta for every five shares of BD held as of March 22, 2022. This strategic move aligns with BD's 2025 plan to enhance long-term shareholder value by allowing both companies to concentrate on their core businesses. Embecta aims to further develop diabetes injection devices, while BD continues to lead in medical and life sciences sectors.
BD (Becton, Dickinson and Company) announced that Alberto Mas will retire as executive vice president and president of the Medical segment, effective September 30, 2022. Mas has served in various leadership roles at BD over nearly 30 years. The company is grateful for his contributions, as stated by CEO Tom Polen, and plans to appoint a successor before Mas's departure. BD continues to focus on advancing healthcare and enhancing the performance of its diverse medical technology solutions.
BD (Becton, Dickinson and Company) announced early results for Morgan Stanley's cash tender offers for specific notes, with a maximum purchase price of $200 million. As of March 29, 2022, holders had validly tendered approximately $1.6 billion in notes, exceeding the maximum limit, which led to a pro-rata acceptance of Floating Rate Notes due June 2022, totaling $199 million. Other notes tendered will not be accepted. The Offers are subject to specific conditions as detailed in the Offer to Purchase.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
